JP2021528046A5 - - Google Patents

Info

Publication number
JP2021528046A5
JP2021528046A5 JP2020560739A JP2020560739A JP2021528046A5 JP 2021528046 A5 JP2021528046 A5 JP 2021528046A5 JP 2020560739 A JP2020560739 A JP 2020560739A JP 2020560739 A JP2020560739 A JP 2020560739A JP 2021528046 A5 JP2021528046 A5 JP 2021528046A5
Authority
JP
Japan
Prior art keywords
cancer
peptide
fragment
seq
cell
Prior art date
Application number
JP2020560739A
Other languages
English (en)
Japanese (ja)
Other versions
JP7579145B2 (ja
JP2021528046A (ja
JPWO2020002063A5 (2
Filing date
Publication date
Priority claimed from DE102018115865.3A external-priority patent/DE102018115865A1/de
Priority claimed from US16/030,725 external-priority patent/US10925947B2/en
Application filed filed Critical
Publication of JP2021528046A publication Critical patent/JP2021528046A/ja
Publication of JP2021528046A5 publication Critical patent/JP2021528046A5/ja
Publication of JPWO2020002063A5 publication Critical patent/JPWO2020002063A5/ja
Priority to JP2024186997A priority Critical patent/JP2025013943A/ja
Application granted granted Critical
Publication of JP7579145B2 publication Critical patent/JP7579145B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020560739A 2018-06-29 2019-06-19 がんに対する免疫療法で使用するためのa*03拘束性ペプチドおよび関連方法 Active JP7579145B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024186997A JP2025013943A (ja) 2018-06-29 2024-10-23 がんに対する免疫療法で使用するためのa*03拘束性ペプチドおよび関連方法

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201862692348P 2018-06-29 2018-06-29
DE102018115865.3A DE102018115865A1 (de) 2018-06-29 2018-06-29 A*03-restringierte Peptide zur Verwendung in der Immuntherapie gegen Krebs und verwandte Verfahren
DE102018115865.3 2018-06-29
US62/692,348 2018-06-29
US16/030,725 US10925947B2 (en) 2018-06-29 2018-07-09 A*03 restricted peptides for use in immunotherapy against cancers and related methods
DE102018116584 2018-07-09
DE102018116584.6 2018-07-09
US16/030,725 2018-07-09
PCT/EP2019/066115 WO2020002063A1 (en) 2018-06-29 2019-06-19 A*03 restricted peptides for use in immunotherapy against cancers and related methods

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024186997A Division JP2025013943A (ja) 2018-06-29 2024-10-23 がんに対する免疫療法で使用するためのa*03拘束性ペプチドおよび関連方法

Publications (4)

Publication Number Publication Date
JP2021528046A JP2021528046A (ja) 2021-10-21
JP2021528046A5 true JP2021528046A5 (2) 2022-06-28
JPWO2020002063A5 JPWO2020002063A5 (2) 2022-06-28
JP7579145B2 JP7579145B2 (ja) 2024-11-07

Family

ID=67070807

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020560739A Active JP7579145B2 (ja) 2018-06-29 2019-06-19 がんに対する免疫療法で使用するためのa*03拘束性ペプチドおよび関連方法
JP2024186997A Pending JP2025013943A (ja) 2018-06-29 2024-10-23 がんに対する免疫療法で使用するためのa*03拘束性ペプチドおよび関連方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024186997A Pending JP2025013943A (ja) 2018-06-29 2024-10-23 がんに対する免疫療法で使用するためのa*03拘束性ペプチドおよび関連方法

Country Status (19)

Country Link
US (12) US10925947B2 (2)
EP (1) EP3813873A1 (2)
JP (2) JP7579145B2 (2)
KR (1) KR20210025534A (2)
CN (2) CN112399853A (2)
AU (1) AU2019294731A1 (2)
BR (1) BR112020022250A2 (2)
CA (1) CA3097698A1 (2)
CL (4) CL2020003371A1 (2)
CO (1) CO2020013659A2 (2)
CR (1) CR20200632A (2)
IL (1) IL279843A (2)
MA (1) MA53004A (2)
MX (1) MX2020012257A (2)
PE (1) PE20211499A1 (2)
PH (1) PH12020552013A1 (2)
SG (1) SG11202009659XA (2)
TW (1) TW202019462A (2)
WO (1) WO2020002063A1 (2)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019020959A2 (pt) * 2017-04-10 2020-05-05 Immatics Biotechnologies Gmbh peptídeos e combinações dos mesmos para uso na imunoterapia contra câncer
AU2021256477A1 (en) * 2020-04-14 2022-11-10 Université de Montréal Novel tumor-specific antigens for acute myeloid leukemia (AML) and uses thereof
KR102620744B1 (ko) 2021-08-18 2024-01-02 주식회사 케이티앤지 니코틴 인헤일러
WO2024077601A1 (en) * 2022-10-14 2024-04-18 Guangdong Tcrcure Biopharma Technology Co., Ltd. Peptide vaccines against glioma and uses thereof
WO2025040598A2 (en) * 2023-08-18 2025-02-27 Immatics Biotechnologies Gmbh Peptides displayed by mhc for use in immunotherapy against different types of cancer
CN119530167A (zh) * 2024-08-30 2025-02-28 江苏亲科生物研究中心有限公司 Scgb1d4单克隆抗体及其试剂盒的制备方法和用途

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440859A (en) 1977-05-27 1984-04-03 The Regents Of The University Of California Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
IL59007A (en) 1978-12-22 1983-11-30 Biogen Nv Recombinant dna molecules coding for polypeptides displaying hepatitis b virus antigenicity,method of their production and compositions containing the same
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US4678751A (en) 1981-09-25 1987-07-07 Genentech, Inc. Hybrid human leukocyte interferons
US4766075A (en) 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
US4582800A (en) 1982-07-12 1986-04-15 Hoffmann-La Roche Inc. Novel vectors and method for controlling interferon expression
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4677063A (en) 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4810648A (en) 1986-01-08 1989-03-07 Rhone Poulenc Agrochimie Haloarylnitrile degrading gene, its use, and cells containing the gene
US4897445A (en) 1986-06-27 1990-01-30 The Administrators Of The Tulane Educational Fund Method for synthesizing a peptide containing a non-peptide bond
US9340577B2 (en) 1992-08-07 2016-05-17 Epimmune Inc. HLA binding motifs and peptides and their uses
AU6852594A (en) 1993-06-03 1995-01-03 Therapeutic Antibodies Inc. Production of antibody fragments
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
US5807978A (en) 1995-06-07 1998-09-15 Kokolus; William J. Immunogenic peptides of prostate specific antigen
ES2203782T3 (es) 1996-01-17 2004-04-16 Imperial College Innovations Limited Inmunoterapia que utiliza linfocitos t citotoxicos (ctl).
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
AUPO500997A0 (en) * 1997-02-07 1997-03-06 Macquarie Research Limited Diagnosis of disease using tears
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US20070020327A1 (en) * 1998-11-10 2007-01-25 John Fikes Inducing cellular immune responses to prostate cancer antigens using peptide and nucleic acid compositions
DE60142475D1 (de) 2000-03-27 2010-08-12 Technion Res And Dev Of Founda Einkettige haupthistokompatibilitätskomplexe der klasse i (mhc-i), kodierende konstrukte und methoden ihrer erzeugung
US20040191260A1 (en) 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
EP2322228B1 (en) 2000-06-05 2018-01-10 Altor BioScience Corporation T cell receptor fusion proteins and conjugates and methods of use thereof
US6992176B2 (en) 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
AU2003216341A1 (en) 2002-02-20 2003-09-09 Dyax Corporation Mhc-peptide complex binding ligands
AU2003271904B2 (en) 2002-10-09 2009-03-05 Adaptimmune Limited Single chain recombinant T cell receptors
DE60327795D1 (de) 2002-11-09 2009-07-09 Immunocore Ltd T zell rezeptor "display"
CA2511775A1 (en) * 2002-12-10 2004-06-24 Epimmune Inc. Hla-a1,-a2 -a3,-a24,-b7,and -b44 tumor associated antigen peptides and compositions
GB0304068D0 (en) 2003-02-22 2003-03-26 Avidex Ltd Substances
ES2341802T3 (es) 2005-09-05 2010-06-28 Immatics Biotechnologies Gmbh Peptidos asociados a tumores unidos promiscuamente a moleculas del antigeno de leucocito humano (hla) de clase ii.
WO2008118017A2 (en) * 2007-03-26 2008-10-02 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Prame derived peptides and immunogenic compositions comprising these
NZ601827A (en) * 2007-10-18 2014-01-31 Bavarian Nordic Inc Use of mva to treat prostate cancer
US20090263574A1 (en) 2008-04-21 2009-10-22 Quinn Daniel E Method of restoring an article
US9840695B2 (en) 2009-04-28 2017-12-12 Agriculture Victoria Services Pty Ltd Plant technology
US9023802B2 (en) 2009-12-14 2015-05-05 Immatics Biotechnologies Gmbh HLA-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
GB201006360D0 (en) 2010-04-16 2010-06-02 Immatics Biotechnologies Gmbh Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
US20140170168A1 (en) 2010-10-26 2014-06-19 Yoram Reiter Antibodies which bind soluble t-cell receptor ligands
WO2013057586A1 (en) 2011-10-19 2013-04-25 Oslo Universitetssykehus Hf Compositions and methods for producing soluble t - cell receptors
US12540318B2 (en) 2012-11-08 2026-02-03 Roche Diagnostics Operations, Inc. Nucleic acids encoding chimeric polypeptides for library screening
EP2808392A1 (en) 2013-05-28 2014-12-03 Rheinische Friedrich-Wilhelms-Universität Bonn Aptamers and use of the aptamers in the diagnosis and treatment of cancer
TWI775117B (zh) * 2013-08-05 2022-08-21 德商伊瑪提克斯生物科技有限公司 新穎肽類,細胞及其用於治療多種腫瘤的用途,其製造方法及包含其等之醫藥組成物(二)
GB201319446D0 (en) 2013-11-04 2013-12-18 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors
GB201411037D0 (en) * 2014-06-20 2014-08-06 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemai (CLL)
MA41218A (fr) * 2014-12-19 2017-10-24 Advaxis Inc Combinaison de vaccin à base de listeria comportant des anticorps anti-ox40 ou anti-gitr
GB201505305D0 (en) 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
CA2988388C (en) * 2015-04-23 2022-11-22 Nantomics, Llc Cancer neoepitopes
GB201513921D0 (en) 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
GB201517538D0 (en) 2015-10-05 2015-11-18 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
GB201520583D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
WO2017089786A1 (en) 2015-11-23 2017-06-01 Immunocore Limited Peptides
EP3383920B1 (en) * 2015-11-30 2024-01-10 The Regents of the University of California Tumor-specific payload delivery and immune activation using a human antibody targeting a highly specific tumor cell surface antigen
RU2020103379A (ru) 2017-07-04 2021-08-04 Куревак Аг Новые молекулы нуклеиновых кислот
US20210061914A1 (en) * 2017-12-28 2021-03-04 Gritstone Oncology, Inc. Antigen-Binding Proteins Targeting Shared Antigens

Similar Documents

Publication Publication Date Title
JP2024041841A5 (2)
JP2024099580A5 (2)
JP2021535900A5 (2)
JP2019511214A5 (2)
JP2020516681A5 (2)
JP2021514178A5 (2)
JP2021528046A5 (2)
JP2021168652A5 (2)
JP2020191862A5 (2)
JP2022502015A5 (2)
JP2019502360A5 (2)
JP2020198875A5 (2)
JP2019510465A5 (2)
EP2951202B1 (en) High avidity binding molecules recognizing mage-a1
JP2018529320A5 (2)
JP2018510628A5 (2)
JP2021101700A5 (2)
JP2019506838A5 (2)
RU2017137142A (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии рака легких, в том числе немелкоклеточного рака легких (нмрл) и других видов рака
JP2018509135A5 (2)
JP2019516663A5 (2)
JP2018536383A5 (2)
JP2018518937A5 (2)
JP2018519243A5 (2)
JP2018511321A5 (2)